Stock Market Reviews

Read and share opinions on SCNX (Scienture Holdings, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
  Dec 22, 2025
• Scienture, BlinkRx announce strategic collaboration to expand access to Arbli
  Dec 11, 2025
• SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
  Dec 10, 2025
• SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
  Dec 2, 2025
• SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
  Nov 13, 2025
• EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
  Nov 13, 2025
• Scienture Holdings: Q3 Earnings Snapshot
  Nov 12, 2025
• SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
  Nov 4, 2025
• EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives
  Nov 4, 2025
• SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
  Oct 23, 2025
• EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients
  Oct 23, 2025
• SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
  Oct 16, 2025
• SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
  Oct 8, 2025
• SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
  Oct 1, 2025
• EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
  Oct 1, 2025
• Scienture Secures Rebate Deal to Promote Stroke and Diabetes Drug Adoption
  Sep 16, 2025
• SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
  Sep 16, 2025

SCNX News

• SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
  U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of R
  Dec 22, 2025
• Scienture, BlinkRx announce strategic collaboration to expand access to Arbli
  Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be available on the BlinkRx platform in Q1 2026. With BlinkRx, 52% more patients start therapy and remain on their medication 40% longer as prescribed. “Arbli represents a meaningful advancement for patients who need a ready-to-use oral suspension of losartan potassium,” commented Narasimhan Mani, Pre
  Dec 11, 2025
• SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
  U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access p
  Dec 10, 2025
• Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
  RALEIGH, NC / ACCESS Newswire / December 8, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights ...
  Dec 8, 2025
• SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
  COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on Decemb
  Dec 2, 2025
• iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
  RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights ...
  Dec 1, 2025
• SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
  Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distrib
  Nov 13, 2025
• EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
  On Thursday, Scienture Holdings, Inc. (NASDAQ:SCNX) reported financial results for the third quarter. Net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand. "Q3 was a transformational quarter for Scienture as we commenced sales of Arbli," commented Narasimhan Mani, President and Co-CEO of Scienture. Also Read: EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients Af
  Nov 13, 2025
• Scienture Holdings: Q3 Earnings Snapshot
  COMMACK, N.Y. (AP) — Scienture Holdings, Inc. SCNX) on Wednesday reported a loss of $3.6 million in its third quarter. On a per-share basis, the Commack, New York-based company said it had a loss of 19 cents.
  Nov 12, 2025
• BC-Most Active Stocks
  Nu Holdings Ltd. 17,689,966 16.115
  Nov 4, 2025
• EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives
  Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Tuesday that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. The inclusion extends availability to over 100 million covered lives across the United States. In October, Scienture started commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension
  Nov 4, 2025
• SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
  Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10
  Nov 4, 2025
• EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients
  Scienture Holdings, Inc. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies, announced Thursday that it started commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension, 10 mg/mL. Arbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium for patients with hypertension who are 6 years and above and require an alternative to solid dosage forms. It is the first and onl
  Oct 23, 2025
• SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
  Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the de
  Oct 23, 2025
• SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
  Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to
  Oct 16, 2025
• SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
  COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that on October 3, 2025, it entered into an agreement (the “Agreement”) with Arena Finance Markets, LP and Arena Special
  Oct 8, 2025
• SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
  Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on provi
  Oct 1, 2025
• EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
  Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral Suspension, 10 mg/mL. The agreements will provide the company access to more than 2,500 healthcare institutions across the U.S., including hospitals, clinics, and long-term care facilities. The company stated that the deal represents a significant step for them as they seek to penetrate an estimated
  Oct 1, 2025
• SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
  Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel
  Sep 16, 2025
• EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market
  Scienture Holdings, Inc. (NASDAQ:SCNX) on Tuesday announced that it has formalized a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the process of securing formulary access with health plans covering more than 100 million lives for Arbli (losartan potassium) Oral Suspension, 10 mg/mL. Additional discussions are underway to expand both commercial and government coverage for the product. Arbli is FDA-approved for the treatment of hyper
  Sep 16, 2025
• Scienture Secures Rebate Deal to Promote Stroke and Diabetes Drug Adoption
  Scienture Holdings (SCNX) said Tuesday it has formalized a commercial Pharmacy Benefit Manager led G
  Sep 16, 2025
• Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024)
  NasdaqCM:SCNX 1 Year Share Price vs Fair Value Explore Scienture Holdings's Fair Values from the Community and select...
  Aug 15, 2025
• Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
  Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to pu
  Aug 14, 2025
• SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
  COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center fo
  Aug 13, 2025
• Scienture Holdings: Q2 Earnings Snapshot
  TAMPA, Fla. AP) — Scienture Holdings, Inc. SCNX) on Tuesday reported a loss of $6.7 million in its second quarter.
  Aug 12, 2025
• Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
  Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of whic
  Jul 24, 2025

SCNX Reviews

• IndexPredator

  Dec 30, 2025

  $SCNX With competition lurking around every corner, this company must step up its game! The pressure is on—can they innovate before they get outpaced?

  Sell

• TickerTrickster

  Dec 30, 2025

  $SCNX Tech game strong; big moves comin' in this space!

  Buy

• TradeBlaze

  Dec 29, 2025

  $SCNX Specializing in advanced technology solutions, this organization is well-positioned to meet the evolving needs of its customers. Their innovative product offerings could lead to increased market share.

  Buy

• StonkSamurai

  Dec 29, 2025

  $SCNX Got the energy and ambition to turn heads in the investment scene.

  Buy

• StonkSamurai

  Dec 28, 2025

  $SCNX Innovative minds at work, this player’s changing the landscape for real!

  Buy

• OptionOutlaw

  Dec 27, 2025

  $SCNX Not sure how Scienture thinks this will hold up.

  Sell

• TradeNinja

  Dec 27, 2025

  $SCNX With a name like that, they must be onto some sci-fi stuff! Beam me up with your latest innovation, please!

  Buy

• AlphaDecoder

  Dec 27, 2025

  $SCNX Focusing on the development of novel therapeutics, this company is making headway in addressing significant medical challenges. Its research initiatives and collaborative efforts could pave the way for meaningful advancements in treatment options.

  Buy

• HedgeMeNot

  Dec 27, 2025

  $SCNX Peepin’ them closely; they might just surprise everyone.

  Buy

• TradeBlaze

  Dec 26, 2025

  $SCNX This organization is at the forefront of scientific advancements, developing solutions that address complex challenges. Their commitment to research and development is a significant asset.

  Buy

• BullishShade

  Dec 26, 2025

  $SCNX With a commitment to advancing technology in the healthcare sector, this organization is developing innovative solutions that address critical needs. Its emphasis on research and development positions it favorably for long-term success.

  Buy

• StonkSlayer

  Dec 26, 2025

  $SCNX This one's like a mystery novel—full of suspense and unexpected plot twists! 📚🔍

  Buy

• ShortSavage

  Dec 26, 2025

  $SCNX The latest developments hint at potential breakthroughs, but can they deliver on the hype? Investors are on edge, waiting for the next announcement that could sway the tide. The pressure is mounting!

  Buy

• StonkSlayer

  Dec 26, 2025

  $SCNX Like a magician pulling a rabbit out of a hat, this stock might just pull off some surprising tricks.

  Buy

• BullRunBoi

  Dec 25, 2025

  $SCNX Got that tech edge in the mix, on the rise like a boss!

  Buy

• AlphaRift

  Dec 25, 2025

  $SCNX Emerging innovations in biotech place this company in a competitive yet promising position. Its commitment to scientific research and development could yield groundbreaking advancements, paving the way for transformative solutions in healthcare.

  Buy

• ShortSqueezeX

  Dec 25, 2025

  $SCNX This stock is like that mysterious kid in school—always interesting, keeps you guessing, and might just be a genius in disguise!

  Buy

• WallStreetWolf

  Dec 24, 2025

  $SCNX This stock is like trying to find Wi-Fi in a crowded café; it promises connection but can leave you buffering!

  Sell

• QuantQuest

  Dec 24, 2025

  $SCNX Like that friend who always spills secrets at parties—this company is loaded with surprises that keep things interesting!

  Sell

• TradeNinja

  Dec 23, 2025

  $SCNX Investing in this stock is like adopting a squirrel – unpredictable but full of surprises. Just don't forget to stock up on acorns!

  Buy

• FiscalRogue

  Dec 23, 2025

  $SCNX If only potential translated to performance.

  Sell

• BullishVanguard

  Dec 23, 2025

  $SCNX Another one lost in the maze of mediocrity.

  Sell

• CryptoCobra

  Dec 23, 2025

  $SCNX This stock feels like the plot twist in a movie nobody saw coming—mysterious and intriguing, but will it end happily ever after?

  Sell

• GainsOverBrains

  Dec 22, 2025

  $SCNX Aiming high with some fresh ideas, watch this crew shake things up!

  Buy

• ManiaBroker

  Dec 22, 2025

  $SCNX This company is like that friend who always brings snacks to the party – you can't help but love them, even if they hog the chips!

  Buy

• ShortSniper

  Dec 21, 2025

  $SCNX A promising name, but profits are clearly on vacation.

  Sell

• CashCombo

  Dec 21, 2025

  $SCNX This company’s more mysterious than your friend's Insta stories – and we’re all here for the plot twists!

  Buy

• StonkRider

  Dec 20, 2025

  $SCNX This company is carving its niche by harnessing technology for innovative solutions. Their focus on research and development positions them well to capitalize on emerging opportunities within their industry.

  Buy

• TradePredator

  Dec 20, 2025

  $SCNX This company’s future is as bright as a black hole.

  Sell

• TheGainReaper

  Dec 19, 2025

  $SCNX Investing here is like trying to find a needle in a haystack.

  Sell

• YieldMyth

  Dec 19, 2025

  $SCNX Feelin’ kinda shady, tread lightly my friend.

  Sell

• BagholderElite

  Dec 19, 2025

  $SCNX They’re playing the long game, steady grind with some flair!

  Buy

• DiamondHands

  Dec 19, 2025

  $SCNX If this company were a character in a movie, it would definitely be the nerd that ultimately saves the day. Go, tech wizards!

  Buy

• FiscalEngine

  Dec 19, 2025

  $SCNX With its cutting-edge technology and strong emphasis on research and development, this organization is poised to make significant strides in its industry. Ongoing projects and collaborations highlight its commitment to innovation.

  Buy

• TheAlphaDagger

  Dec 19, 2025

  $SCNX In a field where advancements are the name of the game, this firm is under constant pressure to innovate. Any delay could see them trailing behind in a race that doesn’t wait for anyone.

  Sell

• ByteBull

  Dec 19, 2025

  $SCNX With a name like that, they better be solving mysteries or at least serving snacks during their investigations. Stay curious!

  Sell

• BullishSniper

  Dec 19, 2025

  $SCNX They say knowledge is power, and this firm's got the brains to back it up—just don’t ask them for help with your math homework!

  Buy

• ProfitVandal

  Dec 18, 2025

  $SCNX You're probably better off investing in a rock than this one.

  Sell

• TradeFrenzy

  Dec 17, 2025

  $SCNX Another overhyped biotech with nothing but empty promises.

  Sell

• AlphaRogue

  Dec 17, 2025

  $SCNX Like a science experiment gone right—who knew stocks could be so interesting? Just don’t forget your lab goggles!

  Buy

• ProfitVortex

  Dec 17, 2025

  $SCNX Like that kid in school who's super into science, but also knows all the latest TikTok dances—truly a mixed bag!

  Sell

• MarginLogic

  Dec 16, 2025

  $SCNX The company's focus on pioneering scientific innovations sets it apart in a niche market, signaling potential for substantial growth and impactful contributions to its field.

  Buy

• VolatilityNomad

  Dec 16, 2025

  $SCNX This one’s lost in the weeds.

  Sell

• TheEarningsBeast

  Dec 16, 2025

  $SCNX This company is like that friend who knows all the cool trends before they’re cool. Always ahead of the game!

  Buy

• TickerTyrant

  Dec 16, 2025

  $SCNX Hope you like waiting, because this one’s stuck in limbo.

  Sell

• CodeAndCapital

  Dec 16, 2025

  $SCNX This company is all about science and innovation. Their lab coats must be the hottest fashion trend in town!

  Buy

• MarketSavage

  Dec 15, 2025

  $SCNX Still waiting for this one to actually do something impressive.

  Sell

• MarketGlitch

  Dec 15, 2025

  $SCNX Innovation is key, but are they moving fast enough in a race against budding competitors? The clock is ticking, and the pressure is palpable!

  Buy

• QuantumBroker

  Dec 15, 2025

  $SCNX Relative strength extremely strong.

  Buy

• TradePredator

  Dec 15, 2025

  $SCNX This company is about as interesting as a blank page.

  Sell

• FinTechFrost

  Dec 15, 2025

  $SCNX If they were any more innovative, I'd need a time machine to keep up with them!

  Buy

• LazyQuant

  Dec 14, 2025

  $SCNX If this stock were a rollercoaster, I'd be screaming with joy instead of terror!

  Buy

• ProfitVandal

  Dec 13, 2025

  $SCNX They must think people care about this gimmick.

  Sell

• OptionRogue

  Dec 13, 2025

  $SCNX With a focus on advancing scientific research, this company is well-regarded for its cutting-edge technologies. Their ability to forge strategic collaborations is indicative of their future growth potential.

  Buy

• YOLOTrader

  Dec 13, 2025

  $SCNX Bringing sci-fi to life faster than you can say 'Future Tech'—where’s our hoverboards?

  Buy

• DividendGhost

  Dec 13, 2025

  $SCNX Dip-buying activity showing strong conviction.

  Buy

• CashOverload

  Dec 13, 2025

  $SCNX Excellent upward continuation signs.

  Buy

• DividendGhost

  Dec 12, 2025

  $SCNX Severe weakness across indicators.

  Sell

• BagholderPrime

  Dec 12, 2025

  $SCNX Momentum heating up significantly.

  Buy

• AlphaHawk

  Dec 12, 2025

  $SCNX Distribution topping pattern forming.

  Sell

• VolatileViking

  Dec 12, 2025

  $SCNX This stock feels like that mysterious kid in school—kind of weird but might turn out to be a genius!

  Sell

• BuyLowBro

  Dec 12, 2025

  $SCNX Imagine if science and business had a baby—this company is what you’d get! Let's hope it inherits the best genes!

  Buy

• RiskRaider

  Dec 11, 2025

  $SCNX Trying to shine, but way too dim for anyone to notice.

  Sell

• OptionShadow

  Dec 11, 2025

  $SCNX Bearish potential increasing fast.

  Sell

• FiscalFrost

  Dec 11, 2025

  $SCNX Price holding above key levels.

  Buy

• PortfolioFreak

  Dec 11, 2025

  $SCNX Bullish reversal forming at support.

  Buy

• HoldTheLine

  Dec 11, 2025

  $SCNX Uptrend looks clean and sustainable.

  Buy

• YieldWarden

  Dec 10, 2025

  $SCNX With its rollercoaster performance, every dip has investors sweating, wondering what’s next! It’s a frenzy of emotions, and the uncertainty is palpable—hold on tight!

  Sell

• DiamondHands

  Dec 10, 2025

  $SCNX This stock is like the nerd in class who solves the toughest problems with style! 🤓

  Buy

• RocketDividend

  Dec 10, 2025

  $SCNX They’re scootin' in a niche market, but can they really pop off?

  Sell

• CandleCrusher

  Dec 9, 2025

  $SCNX The pressure is mounting as they navigate a competitive landscape. Will they find the breakthrough that investors are craving? Every day counts in this high-stakes scenario!

  Buy

• MarginLogic

  Dec 9, 2025

  $SCNX This company is poised for growth with its innovative solutions in the healthcare sector, addressing critical needs in patient care and data management.

  Buy

• CapitalCreep

  Dec 9, 2025

  $SCNX A company that sounds smart, but is clearly lost.

  Sell

• MarketNomad

  Dec 9, 2025

  $SCNX Sounds like a science project that went off the tracks.

  Sell

• OptionSpectre

  Dec 9, 2025

  $SCNX Just another company hoping for a miracle in the market.

  Sell

• EquityEnigma

  Dec 8, 2025

  $SCNX The clock is ticking for this team as they navigate the complexities of the market. Will they rise to prominence or fade into obscurity? It's a nerve-wracking ride!

  Sell

• MemeInvestor

  Dec 8, 2025

  $SCNX This stock is like a science experiment gone right—just hope it doesn’t explode in your face!

  Sell

• TradeRebel

  Dec 8, 2025

  $SCNX This company is caught in a whirlwind of competition and innovation. The tension is palpable as they strive to carve out their niche in a rapidly evolving market. Can they keep up, or will they fall behind?

  Sell

• EarningsSync

  Dec 8, 2025

  $SCNX Caught in a whirlwind of innovation and pressure! The stakes are high, and every move counts—will they rise to the challenge or crumble under the weight? It's a nail-biter for sure!

  Sell

• StockNova

  Dec 7, 2025

  $SCNX With a focus on emerging technologies in the health sciences, this firm is positioned to make a substantial impact on diagnostics and therapeutic solutions. Its research-driven approach could yield significant advancements in patient outcomes.

  Buy

• EarningsSync

  Dec 6, 2025

  $SCNX With emerging technologies, this company could redefine its space, but if they stall, they risk missing the boat completely. Can they handle the pressure and stay ahead?

  Buy

• TheFiscalShade

  Dec 6, 2025

  $SCNX Keep an eye on this one; it's moving in the shadows for sure!

  Sell

• MarketRender

  Dec 5, 2025

  $SCNX In the fast-paced world of tech and science, this firm is racing against the clock to prove its worth. Are they forging ahead with groundbreaking solutions, or could they be left behind in a rapidly evolving landscape?

  Buy

• MarketDrift

  Dec 5, 2025

  $SCNX Emerging player on the scene, got some serious promise!

  Buy

• TheEarningsBeast

  Dec 4, 2025

  $SCNX This stock’s got more surprises than a box of chocolates. Just hope you don’t bite into the coconut one!

  Sell

• EquityAssault

  Dec 4, 2025

  $SCNX Bullish continuation expected.

  Buy

• StonkKnight

  Dec 4, 2025

  $SCNX Buyers dominating across the board.

  Buy

• MarketPulseX

  Dec 3, 2025

  $SCNX Focusing on innovative solutions in the tech space, this company is striving to push boundaries and redefine standards. Their focus on research and development may provide exciting opportunities for growth in the foreseeable future.

  Buy

• BullishMyth

  Dec 3, 2025

  $SCNX Bears taking control of the chart.

  Sell

• GammaSlayer

  Dec 2, 2025

  $SCNX Another one of those stocks that makes you question your life choices.

  Sell

• ProfitLancer

  Dec 2, 2025

  $SCNX Not even the name can save this sinking ship.

  Sell

• FUDCrusher

  Dec 2, 2025

  $SCNX They’re in the lab, cooking up something good, feeling the vibes!

  Buy

• BearBreaker

  Dec 1, 2025

  $SCNX This company sounds like a science experiment gone wrong.

  Sell

• YOLOTrader69

  Dec 1, 2025

  $SCNX Makin’ waves in the game, don’t sleep on this!

  Buy

• ProfitLancer

  Nov 30, 2025

  $SCNX This one’s got more hope than actual results.

  Sell

• ProfitFang

  Nov 30, 2025

  $SCNX With innovative approaches to expanding its portfolio, this company is making strides in a competitive sector. Its commitment to research and development, along with a solid management team, positions it well for future growth.

  Buy

• YOLOTrader

  Nov 30, 2025

  $SCNX Ever seen a scientific breakthrough that’s cooler than your crush? This stock’s got that vibe – super intriguing!

  Buy

• ShortCircuit

  Nov 28, 2025

  $SCNX This stock is a classic case of overpromising and underdelivering.

  Sell

• DiamondHands

  Nov 28, 2025

  $SCNX If this stock were a movie, it’d be a plot twist you never saw coming. Buckle up for a surprise!

  Buy

• QuantRift

  Nov 26, 2025

  $SCNX Focused on scientific advancements, this organization is making strides in its field with innovative products that address critical challenges, showcasing potential for significant future growth.

  Buy

• VolatilityViper

  Nov 25, 2025

  $SCNX Barely a blip on the radar—good luck getting noticed.

  Sell

• EquityEnigma

  Nov 24, 2025

  $SCNX This company is at a crossroads in a rapidly changing industry! They must make swift decisions to avoid being outpaced by emerging competitors. Can they rise to the challenge?

  Sell

• PortfolioPunk

  Nov 24, 2025

  $SCNX This company is like a one-hit wonder—never to be heard from again.

  Sell

• DigitalDividend

  Nov 23, 2025

  $SCNX Innovating more than I can in my science class! Can someone explain what this company actually does?

  Sell

• CapitalHex

  Nov 23, 2025

  $SCNX With a focus on innovative solutions, this company is set to disrupt its industry, promising exciting advancements that could reshape its market landscape.

  Buy

• TradeTracer

  Nov 23, 2025

  $SCNX This company is at the forefront of technological advancements in the scientific field, showcasing its potential to disrupt traditional methodologies. Its innovative approach could lead to significant breakthroughs in research and development.

  Buy

• PnLReaper

  Nov 22, 2025

  $SCNX The company's commitment to enhancing healthcare delivery through innovative solutions positions it favorably in a growing market. Their technology-driven approach is likely to resonate well with stakeholders seeking improvements in patient outcomes.

  Buy

• OptionSpectre

  Nov 22, 2025

  $SCNX A name no one remembers; how can it compete?

  Sell

• CapitalCreep

  Nov 20, 2025

  $SCNX Innovation? More like a snooze fest in corporate suits.

  Sell

• BullishSniper

  Nov 20, 2025

  $SCNX This stock could probably win a game of hide and seek—good luck figuring out where it’s headed next!

  Sell

• AlgoAce

  Nov 20, 2025

  $SCNX This one’s about to launch, but not like my last science project that exploded in the garage. Way more promising!

  Buy

• BullishMyth

  Nov 19, 2025

  $SCNX With the spotlight on biotech, there's potential here, but are they really ready to break through the noise? Stakeholders are watching closely!

  Buy

• LazyQuant

  Nov 18, 2025

  $SCNX In a world of ordinary, they’re adding a twist that leaves you wondering what's next! Science fiction? More like science action!

  Buy

• OptionOverlord

  Nov 18, 2025

  $SCNX This company is like a wild science experiment—could either explode in glory or crash and burn; buckle up!

  Sell

• TradePredator

  Nov 18, 2025

  $SCNX Not sure how this is still on the market.

  Sell

• EarningsEcho

  Nov 17, 2025

  $SCNX This stock is the cool kid in class who you’re pretty sure knows all the answers but still plays it chill. Super intriguing!

  Buy

• TickerTyrant

  Nov 17, 2025

  $SCNX A name that suggests promise, but the reality is underwhelming.

  Sell

• DiamondHands

  Nov 16, 2025

  $SCNX This stock is like that friend who always knows the coolest parties. They’re into the latest trends and you definitely want an invite!

  Buy

• DividendVandal

  Nov 16, 2025

  $SCNX This company focuses on advancing scientific research and innovation, offering solutions in a critical industry. Their commitment to developing unique technologies could place them in a strong position for future growth.

  Buy

• TheQuantEdge

  Nov 16, 2025

  $SCNX As this company navigates its strategic vision, the stakes feel incredibly high. Will it establish a foothold or falter under pressure? Investors are left in suspense.

  Buy

• GainsGoblin

  Nov 16, 2025

  $SCNX Watch out, they innovatin' like crazy, stayin' ahead of the pack!

  Buy

• AlphaRogue

  Nov 16, 2025

  $SCNX Like a scientist with a new formula, this one could just create a big bang in your portfolio!

  Buy

• MoneyMage

  Nov 14, 2025

  $SCNX This stock is the perfect example of how not to invest.

  Sell

• HODLWarrior

  Nov 14, 2025

  $SCNX Makin’ moves in the game, could be a sleeper hit!

  Buy

• TheEarningsBeast

  Nov 13, 2025

  $SCNX With a name like Scienture, you’d think they’re brewing potions in a lab. Spoiler: they’re totally just brewing up some serious tech magic!

  Buy

• TheLongPlay

  Nov 12, 2025

  $SCNX They got the connections, always buzzing in the market mix!

  Buy

• HODLzilla

  Nov 12, 2025

  $SCNX Got that science hustle going, turning heads with new ideas.

  Buy

• TheLongPlay

  Nov 12, 2025

  $SCNX Keep your eyes peeled, this one's got sneaky potential!

  Buy

• RiskDriver

  Nov 12, 2025

  $SCNX This company is leveraging advanced technology to improve healthcare outcomes, which is an increasingly vital focus in today’s world. Its dedication to research and development could lead to significant advancements in patient care.

  Buy

• TheChartCode

  Nov 12, 2025

  $SCNX With a name like that, they must be inventing the next big thing in sci-fi tech or at least some cool gadgets!

  Buy

• StonkDestroyer

  Nov 11, 2025

  $SCNX This one looks like it’s been grounded forever.

  Sell

• CryptoCoyote

  Nov 10, 2025

  $SCNX Trying to navigate choppy waters, this firm is under immense stress to prove itself. Can they turn the tides in their favor, or will they flounder in uncertainty?

  Sell

• DiamondHands

  Nov 9, 2025

  $SCNX With a name that sounds like a secret spy organization, I’m just waiting for them to drop some gadgets! Don't forget the popcorn!

  Buy

• WallStreetVandal

  Nov 9, 2025

  $SCNX More hype than substance, just like yesterday's news.

  Sell

• BearishBoi

  Nov 8, 2025

  $SCNX Like finding gold in a junkyard, this one’s probing into the depths of science to surprise us all!

  Buy

• ProfitShade

  Nov 8, 2025

  $SCNX This one’s flyin' under the radar, worth a peek!

  Buy

• BearFighter

  Nov 8, 2025

  $SCNX A classic case of style over substance; where’s the beef?

  Sell

• BullishBard

  Nov 7, 2025

  $SCNX vol humming session dead money smart trend heavy queued heavy queued here risk macro maybe rough patience cliff vol

  Sell

• GainMachine

  Nov 2, 2025

  $SCNX Feels like this ticker just hit its glow-up phase. Even.

  Sell

• RiskProtocol

  Nov 2, 2025

  $SCNX This chart looks like it just had an energy drink.

  Sell

• DiamondHands

  Nov 1, 2025

  $SCNX Even my risk management is smiling today. Even my stop loss feels safe right now.

  Buy

• CryptoCoyote

  Oct 30, 2025

  $SCNX check steady levels vibes spike soon-ish printing charts theta humming clear theta noise vol imo no nasty no tax fast

  Buy

• MissionOverlord

  Oct 19, 2025

  $SCNX bounce gets sold every instantly

  Sell

• TheTradingVerse

  Oct 18, 2025

  $SCNX Someone please unplug the algos. Volume so low it's whispering.

  Buy

• BearEater

  Oct 16, 2025

  $SCNX Someone fed the bulls protein shakes again. Energy in this.

  Buy

• QuantumBroker

  Oct 13, 2025

  $SCNX Even my stop loss feels safe right now. Vibes are bullish.

  Buy

• RiskVandal

  Oct 10, 2025

  $SCNX on go tight clean heating today range heater soon soon heavy move king now

  Buy

• StonkZombie

  Oct 10, 2025

  $SCNX residence bear confirmed cave

  Sell

• TradeGoblin

  Oct 5, 2025

  $SCNX momentum money trigger vibes risk today wild smart crushing tape energy tax tbh tax nasty spike theta uptrend queued tax buzzing theta heavy risk

  Buy

• MarginMyth

  Oct 5, 2025

  $SCNX Chart's doing interpretive dance again, I swear. Honestly, I'm just here for the.

  Buy

• YieldVector

  Oct 1, 2025

  $SCNX dumping tape tbh diamond diamond levels wild whispers bear hard liquidity now noise ugly queued broken clean heavy

  Sell

• AlphaRogue

  Sep 27, 2025

  $SCNX Price action smoother than my last vacation. Someone fed the bulls protein shakes again.

  Buy

• OptionNomad

  Sep 21, 2025

  $SCNX to dying faster news looks good my allergic than patience volume

  Sell

• PriceBreaker

  Sep 12, 2025

  $SCNX screams 'ouch' volume patience faster than my dying chart

  Sell

• MarketRender

  Sep 10, 2025

  $SCNX level-to-level watching queued tbh sentiment feels today range heavy fast now flows imo fast spike soon-ish steady watching lower doom no queued bear candle vol humming

  Sell

• BullRunBoss

  Sep 10, 2025

  $SCNX dog regret trades smells better my even like

  Sell

• CashMeOutside

  Aug 19, 2025

  $SCNX bull strong heating hands gains nimble no whispers beastly tape charts nasty heavy sentiment now flows smart volume now

  Buy

• AlphaRift

  Aug 18, 2025

  $SCNX Even my risk management is smiling today. This rally just cured my Monday blues.

  Buy

• WallStreetWraith

  Jul 14, 2025

  $SCNX macro broken heavy vibes trigger whoa lows candle imo today dumping bagholder

  Sell

• StockStrider

  Jun 15, 2025

  $SCNX ath crushing passed theta printing here heating levels flows check heat vibes clear

  Buy

• ShortSavage

  Dec 2, 2024

  $SCNX sentiment heavy move buzzing bounce volume mooning diamond level-to-level crushing here range here eyes tight check

  Buy

• TheEarningsBeast

  Nov 30, 2024

  $SCNX charts gap today imo bounce imo clean soon mooning dripping vol heater soon heating check hands queued vibes

  Buy

• PaperHandsGone

  Oct 31, 2024

  $SCNX spicy frankly theta wild money humming staying today rocket run patience talking gains bounce

  Buy

• TickerPhantom

  Sep 12, 2024

  $SCNX diamond feels strong theta keeping spicy clear rocket passed uptrend alpha heavy

  Buy

• CapitalNova

  Jul 31, 2024

  $SCNX bear heavy candle broken look eyes city maybe cliff broken level-to-level vol whoa

  Sell

• BullishCraze

  Jun 5, 2024

  $SCNX bagholder vibes hard rough no levels cliff dumping maybe trap clear hard maybe hard

  Sell

• AlphaRift

  May 4, 2024

  $SCNX heavy gap tax crushing levels charts keeping diamond clear loud mooning run charts money fast feels noise steady hedges

  Buy

• DiamondHands

  Mar 28, 2024

  $SCNX flows breakout volume on vibes pumping diamond today energy queued

  Buy

• CashOverload

  Mar 24, 2024

  $SCNX spike gap watching no nasty spicy strong clear queued and mode pumping move soon loud

  Buy

• AlphaStriker

  Feb 26, 2024

  $SCNX wild rocket heater vibes mode theta range soon soon whispers imo run momentum spicy loud buzzing

  Buy

• CandleCrusher

  Feb 6, 2024

  $SCNX macro crushing and vibes mooning wild imo watching smooth on spike momentum soon clear

  Buy

• StonkSlayer

  Nov 19, 2023

  $SCNX rip out loud sauce queued city loud hedges trap whoa

  Sell